How should the tacrolimus dose be adjusted for a heart transplant patient with a trough level of 28 ng/mL who is currently taking 0.5 mg tablets, two in the morning and one in the evening?

Immediate Dose Reduction Required for Supratherapeutic Tacrolimus Level

Hold tacrolimus immediately and reduce the total daily dose by approximately 50% when restarting, then recheck the level in 2-3 days. A trough level of 28 ng/mL is dangerously elevated and places this heart transplant patient at significant risk for nephrotoxicity and other serious adverse effects 1.

Current Situation Analysis

Your patient is taking:

• Morning: 1.0 mg (two 0.5 mg tablets)
• Evening: 0.5 mg (one 0.5 mg tablet)
• Total daily dose: 1.5 mg/day
• Current level: 28 ng/mL

The therapeutic target range for heart transplant recipients is 10-20 ng/mL in the early post-transplant period, with some centers targeting as low as 5-20 ng/mL 2, 3, 4. Your patient's level of 28 ng/mL exceeds this by 40-180%.

Specific Dose Adjustment Protocol

Step 1: Hold Doses

• Skip the next 1-2 doses (hold for 12-24 hours depending on when the level was drawn)
• This allows the level to decline given tacrolimus's half-life of approximately 23.6 hours in heart transplant patients 1

Step 2: Resume at Reduced Dose

After holding, restart at approximately 50% of current dose:

• New morning dose: 0.5 mg (one 0.5 mg tablet)
• New evening dose: 0.5 mg (one 0.5 mg tablet)
• New total daily dose: 1.0 mg/day

Alternatively, you could use an asymmetric split:

• Morning: 0.5 mg
• Evening: 0 mg (skip evening dose entirely)
• Total: 0.5 mg/day

Step 3: Recheck Level

• Draw trough level in 2-3 days (before morning dose)
• Target range: 10-20 ng/mL

Step 4: Further Titration

Based on the new level:

• If 15-20 ng/mL: Continue current dose
• If 10-15 ng/mL: Consider this acceptable; may increase slightly if clinically indicated
• If <10 ng/mL: Increase by 0.5 mg/day increments
• If >20 ng/mL: Reduce further by 25-33%

Critical Considerations

Trough levels correlate strongly with AUC (correlation coefficient 0.89 in heart transplant patients) 1, making them reliable markers of systemic exposure. Research demonstrates that maintaining levels of 10-20 ng/mL provides optimal rejection prophylaxis while minimizing toxicity 2.

Rejection risk at supratherapeutic levels: Paradoxically, you're not at increased rejection risk with this high level—the concern is toxicity, particularly nephrotoxicity. Studies show that levels below 8 ng/mL at day +5 post-transplant increase rejection risk 1.58-fold 4, but your patient is well above this threshold.

Pharmacokinetic variability: Tacrolimus exhibits significant interpatient variability due to factors including CYP3A5 genotype, drug interactions, and food effects 1, 5. The FDA label emphasizes that food decreases absorption by 37% (AUC) and 77% (Cmax) 1, so ensure consistent administration relative to meals.

Common Pitfalls to Avoid

1. Don't make small adjustments: A 28 ng/mL level requires aggressive reduction, not minor tweaking. Small dose changes (10-20%) will leave the patient toxic for too long.

2. Don't forget drug interactions: Review all medications for CYP3A4/5 inhibitors (azoles, macrolides, calcium channel blockers) or inducers (rifampin, phenytoin) that may have been recently added or removed.

3. Don't ignore food timing: Tacrolimus should be taken consistently—either always with food or always fasted. The FDA label shows food reduces absorption dramatically 1.

4. Don't wait too long to recheck: With a level this high, waiting a week is too long. Recheck in 2-3 days to ensure you're trending toward target.

Monitoring Beyond the Immediate Crisis

Once stabilized in the 10-20 ng/mL range:

• Frequency: Weekly levels initially, then every 2 weeks, then monthly as stable
• Renal function: Monitor creatinine closely—slow metabolizers (high C/D ratio) have 3.72-fold increased risk of acute kidney injury 6
• Rejection surveillance: Continue scheduled endomyocardial biopsies per your center's protocol

Recent evidence suggests that intragraft tacrolimus levels may better predict rejection than whole blood levels 7, but this is not yet standard practice. For now, maintain whole blood trough monitoring as the clinical standard.